Dr. Henry N. Ginsberg is a distinguished physician-scientist and leader in cardiometabolic medicine at Columbia University. He currently serves as the Irving Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons and holds the title of Director Emeritus of the Irving Institute for Clinical and Translational Research. Dr. Ginsberg earned his medical degree from the State University of New York Downstate Medical Center and completed his internal medicine training at Boston City Hospital before specializing in endocrinology and metabolism at Stanford University Medical Center. For over two decades, he directed Columbia's Irving Institute, establishing it as a premier center for clinical translational research while serving as Associate Dean for Clinical and Translational Research.
Dr. Ginsberg's pioneering research has fundamentally advanced understanding of lipid metabolism, particularly the regulation of apolipoprotein B-containing lipoproteins in cellular, animal, and human models. His work on the interplay between very low-density lipoprotein secretion and hepatic steatosis has provided critical insights into cardiovascular risk factors and metabolic disease pathogenesis. As co-principal investigator for Columbia on the landmark ACCORD Trial and lead author of the influential ACCORD Lipid study published in The New England Journal of Medicine, his findings have directly shaped clinical guidelines for cardiovascular risk management in diabetes. With over 250 peer-reviewed scientific publications and more than 100 reviews and chapters, his sustained NIH funding spanning more than 40 years includes a recent Outstanding Investigator Award providing $4 million in support over seven years.
Beyond his research contributions, Dr. Ginsberg has profoundly influenced the field through leadership in major professional organizations and training the next generation of physician-scientists. He maintains active roles in the American Heart Association and American Diabetes Association, holding fellowships in multiple AHA councils and the American Association for the Advancement of Science while serving as a member of both the American Society for Clinical Investigation and the Association of American Physicians. His dedication to education is evident through his long-standing directorship of the T32 Postdoctoral Training Grant in Arteriosclerosis and leadership of Columbia's CTSA-funded training programs, including predoctoral, master's, and junior faculty development initiatives. Currently focusing on human mutations affecting hepatic lipid and lipoprotein metabolism, Dr. Ginsberg continues to drive innovation at the intersection of basic science and clinical application, cementing his legacy as a transformative figure in metabolic medicine.
